Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 52

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Type 2 diabetes mellitus

Not recruiting

Study of Orforglipron for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Eli Lilly & Co.

Diabetic neuropathy

Not recruiting

Study of LY3556050 for Adults with Diabetic Peripheral Neuropathy Pain

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LY3556050
  • Sponsor:Eli Lilly & Co.

Porphyria non-acute

Not recruiting

Study of Afamelanotide for Patients with Erythropoietic Protoporphyria (EPP)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Afamelanotide
  • Sponsor:Clinuvel Europe Limited

Hyperkalaemia+2

Not recruiting

Study on Sodium Zirconium Cyclosilicate for Patients with Chronic Kidney Disease Stages 3b and 4 to Allow More Fruits and Vegetables in Their Diet

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Leiden University Medical Center

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Effectiveness of LASN01 for Patients with Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LASN01
  • Sponsor:Lassen Therapeutics 1 Inc.

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting

Study on the Effects and Safety of INZ-701 for Children with ENPP1 Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Metabolic dysfunction-associated liver disease

Not recruiting

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:GSK4532990A
  • Sponsor:Glaxosmithkline Research & Development Limited

Arteriosclerosis+1

Not recruiting

Study on the Safety and Effects of INZ-701 for Infants with ENPP1 or ABCC6 Deficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Porphyria non-acute

Not recruiting

Study on the Effects of Dersimelagon Phosphate for Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate
  • Sponsor:Tanabe Pharma America Inc.

Primary hyperaldosteronism

Not recruiting

Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Assistance Publique Hopitaux De Paris

Type 2 diabetes mellitus+2

Not recruiting

Study on Testosterone Undecanoate Effects on Liver Fat in Obese Men with Low Testosterone and Type 2 Diabetes or Prediabetes

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Testosterone Undecanoate
  • Sponsor:Medical University Of Vienna

PIK3CA related overgrowth spectrum

Not recruiting

Study on the Long-Term Safety of Alpelisib for Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.